Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04199468 · ClinicalTrials.gov registry record · Phase 1
THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT04199468 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 22 participants.
The verdict
NCT04199468, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The aim of the research protocol is to evaluate cannabinoid-glutamate interactions in humans. As part of this aim the investigators will assess the safety and tolerability of the combination of NMDA antagonist, ketamine, and the cannabinoid, delta-9-tetrahydrocannabinol (THC), in healthy adult subjects, and characterize the interactive effects of ketamine and THC on various electrophysiological (EEG), cognitive, and behavioral outcomes.
Interventions
- DRUG Active Delta-9-THC
- DRUG Placebo Delta-9-THC
- DRUG Active Ketamine
- DRUG Placebo Ketamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2019-09-24 |
| Est. Completion | 2022-06-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04199468
The ClinicalTrials.gov registry entry for NCT04199468 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Active Delta-9-THC is the first listed.
NCT04199468 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04199468 about?
NCT04199468 is a clinical study titled "THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis". The aim of the research protocol is to evaluate cannabinoid-glutamate interactions in humans. As part of this aim the investigators will assess the safety and tolerability of the combination of NMDA antagonist, ketamine, and the cannabinoid, delta-9-tetrahydrocannabinol (THC), in healthy adult subje...
What is the current status of trial NCT04199468?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2019-09-24. Estimated completion is 2022-06-21.
What interventions are being tested in trial NCT04199468?
The interventions under investigation include: Active Delta-9-THC (DRUG), Placebo Delta-9-THC (DRUG), Active Ketamine (DRUG), Placebo Ketamine (DRUG).
Who is sponsoring clinical trial NCT04199468?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.